Overview

Bioequivalence Study of Didanosine in Children Treated for HIV

Status:
Suspended
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to show that the administration of 400/mg/m2/day of didanosine(ddI) during the meal is bioequivalent to the administration of 240/mg/m2/day of didanosine during fasting, in HIV infected children treated by a ARV combination including ddI
Phase:
Phase 2
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Treatments:
Didanosine